bioAffinity Technologies, Inc.

BIAF Healthcare Diagnostics & Research

In the quarter to June 2026, revenue grew 19.0%, EPS grew 87.5%, free cash flow fell 23.7% and total debt rose 569.7%, each against the same quarter a year earlier.

3.73 0.23 −5.81%
Market cap
$5.1M
P/E
0.0×
Fwd P/E
−0.2×
Dividend yield
—
F-score
2/9
Altman Z
−10.54
Beneish M
−5.49
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
3 2 2 3

+8 more TTM periods

ROE
(1,860.15%) (622.65%) (301.83%) (245.18%)
ROA
(245.51%) (235.39%) (170.65%) (162.88%)
ROIC
(408.67%) (613.56%) (438.42%) (458.54%)
Return on Tangible Assets
(1,013.64%) (1,131.70%) (302.76%) (224.78%)
Average Days of Receivables
55.35 44.19 32.10 24.18
Free Cash Flow per Share
(33.16) (36.46) (81.79) (119.65)
Free Cash Flow
(11.56) (10.93) (9.39) (8.51)
Capital Expenditures
(0.09) (0.02) (0.06) (0.06)
Other line items
Cash ROIC
(171.18%) (148.21%) (65.17%) (50.78%)
Accounts Receivable Turnover
8.96 6.87 7.33 7.63
Accounts Payable Turnover
3.61 3.42 4.83 5.67
Inventory Turnover
61.06 64.91 104.24 161.35
Average Days of Payables
91.73 80.58 65.79 70.24
Days of Inventory on Hand
7.79 7.51 4.62 2.63
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
45.14% 40.06% 33.90% 28.60%
Selling, General and Administrative Expense of Revenue
192.29% 189.10% 160.88% 144.56%
Share Based Compensation of Revenue
15.80% 6.35% 10.90% 12.39%
Interest Coverage
(275.76) (264.59) (237.58) (184.08)
Operating CF/Net income
0.76 0.69 0.63 0.57
Depreciation/Fixed assets
1.32 1.88 1.90 1.76
Capex/Depreciation
(0.22) (0.03) (0.12) (0.11)
Revenue per Share
16.93 18.88 53.68 95.31
Operating CF per Share
(32.90) (36.40) (81.26) (118.80)
Capex per Share
(0.26) (0.05) (0.53) (0.85)
Capex to Sales
0.02 0.00 0.01 0.01

Fold the line items

Columns are period end dates · fundamentals updated 2 Oct 2026